Journal: World Journal of Surgical Oncology

Article Title: ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer

doi: 10.1186/s12957-026-04227-4

Figure Lengend Snippet: Prevalence of ERBB2 mutations in gallbladder cancer and identification of an ERBB2 I655V mutation potentially associated with response to immunotherapy. ( A ) Whole-exome sequencing results from a gallbladder cancer specimen identified an ERBB2 I655V mutation. The table presents genomic coordinates, reference and variant alleles, exonic function, dbSNP ID, and minor allele frequency (MAF) from the 1000 Genomes and gnomAD databases. ( B ) Genetic alterations in receptor tyrosine kinase (RTK) signaling pathway genes across three gallbladder cancer cohorts from cBioPortal. Alteration frequencies are shown on the left, with ERBB2 exhibiting the highest mutation rate (13%). Mutation types are color-coded as indicated

Article Snippet: The pcDNA3.1(+)-Puro plasmid containing the wild-type ERBB2 gene was obtained from Biosun Company.

Techniques: Mutagenesis, Sequencing, Variant Assay

Journal: World Journal of Surgical Oncology

Article Title: ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer

doi: 10.1186/s12957-026-04227-4

Figure Lengend Snippet: The ERBB2 I655V mutation may stabilize heterodimerization of ERBB family receptors, leading to enhanced downstream signaling. ( A ) Multiple sequence alignment of the GG4-like motif within the transmembrane domain of ERBB2 (HER2) across different ERBB (HER) family members and various species. The alignment shows that I655 is evolutionarily conserved in ERBB2. ( B ) Structural comparison of the ERBB2 transmembrane domain in inactive (left) and active (right) conformations. The I655V substitution may disrupt heterodimerization of HER2 by altering hydrophobic interactions. ( C ) Inactive (left) and active (right) structural conformations of ERBB2, illustrating the spatial arrangement of key residues at the dimerization interface. ( D ) Schematic representation of the conformational transition from inactive to active ERBB2

Article Snippet: The pcDNA3.1(+)-Puro plasmid containing the wild-type ERBB2 gene was obtained from Biosun Company.

Techniques: Mutagenesis, Sequencing, Comparison

Journal: World Journal of Surgical Oncology

Article Title: ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer

doi: 10.1186/s12957-026-04227-4

Figure Lengend Snippet: The ERBB2 I655V mutation activates downstream signaling pathways and promotes an immunosuppressive tumor microenvironment in gallbladder cancer (GBC). ( A ) GO and REACTOME pathway enrichment analysis of differentially expressed genes. ( B ) RT-qPCR analysis of VEGFA mRNA expression in GBCSD and SGC996 cells expressing wild-type ERBB2 or ERBB2 I655V mutant. ( C ) Western blot analysis of GBCSD and SGC996 cells transfected with empty vector, wild-type ERBB2, or ERBB2 I655V. ( D ) Bubble plot depicting the correlation between ERBB2 expression and CD8 + T cell infiltration. UCEC: Uterine Corpus Endometrial Carcinoma; THYM: Thymoma; THCA: Thyroid Carcinoma; TGCT: Testicular Germ Cell Tumor; STAD: Stomach Adenocarcinoma; SKCM: Skin Cutaneous Melanoma; SKCM-Meta: Skin Cutaneous Melanoma - Metastasis; SARC: Sarcoma; PAAD: Pancreatic Adenocarcinoma; LUSC: Lung Squamous Cell Carcinoma; LUAD: Lung Adenocarcinoma; LIHC: Liver Hepatocellular Carcinoma; KIRP: Kidney Renal Papillary Cell Carcinoma; KIRC: Kidney Renal Clear Cell Carcinoma; DLBC: Diffuse Large B-cell Lymphoma; Breast Invasive Carcinoma; BRCA-Basal: Breast Invasive Carcinoma - Basal subtype

Article Snippet: The pcDNA3.1(+)-Puro plasmid containing the wild-type ERBB2 gene was obtained from Biosun Company.

Techniques: Mutagenesis, Protein-Protein interactions, Quantitative RT-PCR, Expressing, Western Blot, Transfection, Plasmid Preparation